Program Overview
Herpes zoster is the clinical manifestation of varicella-zoster virus (VZV) reactivation, which results from waning VZV immunity, a common consequence of aging. Approximately 1 million individuals in the United States annually are afflicted with herpes zoster. One of the most common clinical complications associated with herpes zoster is the painful condition known as postherpetic neuralgia (PHN). Although agents commonly used to treat PHN have some degree of efficacy, pain relief is almost always only partial and may be associated with many adverse reactions. However, many cases of herpes zoster, and possibly some cases of PHN, can be prevented by herpes zoster vaccination. Clinical trial data have shown significant reductions in the overall burden of disease due to herpes zoster, as well as the incidence of herpes zoster and PHN. Thus, herpes zoster vaccination is recommended by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices for all individuals ≥60 years of age who have no contraindications, including persons who report a previous episode of herpes zoster and persons with chronic medical conditions (eg, chronic renal failure, diabetes mellitus, rheumatoid arthritis, and chronic pulmonary disease).
This activity will review the epidemiology of herpes zoster and PHN, the burden of illness associated with these conditions, the management of herpes zoster and PHN, clinical trial data for the herpes zoster vaccine, as well as the latest CDC recommendations. Participants will evaluate the clinical benefit of herpes zoster vaccination through interactive patient case studies that will feature situations typically encountered by health care providers.
